awmsg logo



peginterferon beta-1a (Plegridy®)


Reference No. 2013

Publication date:
16/07/2015


Appraisal information

peginterferon beta-1a (Plegridy®) 125 micrograms solution for injection
peginterferon beta-1a (Plegridy®) 63 micrograms solution for injection
peginterferon beta-1a (Plegridy®) 94 micrograms solution for injection


Company: Biogen Idec Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/05/2015
AWMSG meeting date: 17/06/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1615
Ministerial ratification: 15/07/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Peginterferon beta-1a (Plegridy®) is recommended as an option for use within NHS Wales in adult patients for the treatment of relapsing remitting multiple sclerosis.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download